London-based COMPASS Pathways plc (Nasdaq: CMPS) has secured $285 million in private funding to advance the company toward offering psychedelics as a treatment for mental health conditions.The company appears to see a clear path toward FDA approval and has convinced several investors of the opportunity. COMPASS Pathways named 11 investment firms and hinted at others […]
